StreetInsider.com News Articles

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial

Tue, 16 Jun 2026 07:32:00 -0400

Vancouver, Canada, June 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of dosing for all 24 participants in Cohorts 1 through 4 of Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD).

All healthy participants in the first stage of the trial have been treated with escalating dose levels of the Company’s

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial

Tue, 16 Jun 2026 07:32:00 -0400

All healthy participants in the first stage of the trial have been treated with escalating dose levels of the Company’s

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial

Tue, 16 Jun 2026 07:32:00 -0400

All healthy participants in the first stage of the trial have been treated with escalating dose levels of the Company’s

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial

Tue, 16 Jun 2026 07:32:00 -0400

All healthy participants in the first stage of the trial have been treated with escalating dose levels of the Company’s

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial

Tue, 16 Jun 2026 07:32:00 -0400

All healthy participants in the first stage of the trial have been treated with escalating dose levels of the Company’s

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial

Tue, 16 Jun 2026 07:32:00 -0400

All healthy participants in the first stage of the trial have been treated with escalating dose levels of the Company’s

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial

Tue, 16 Jun 2026 07:32:00 -0400

All healthy participants in the first stage of the trial have been treated with escalating dose levels of the Company’s

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial

Tue, 16 Jun 2026 07:32:00 -0400

All healthy participants in the first stage of the trial have been treated with escalating dose levels of the Company’s

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial

Tue, 16 Jun 2026 07:32:00 -0400

All healthy participants in the first stage of the trial have been treated with escalating dose levels of the Company’s

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial

Tue, 16 Jun 2026 07:32:00 -0400

All healthy participants in the first stage of the trial have been treated with escalating dose levels of the Company’s

Clearmind Medicine receives Johns Hopkins approval for CMND-100 trial parts

Tue, 26 May 2026 08:25:29 -0400

Clearmind Medicine Inc. (NASDAQ: CMND) received approval from the Johns Hopkins Medicine Institutional Review Board to advance its Phase I/II clinical trial of CMND-100 to Parts B and C, the company announced May 26.

The multicenter study examines single and multiple dose tolerability, safety and pharmacokinetics of CMND-100 in healthy volunteers and subjects with alcohol use disorder. The approval permits the company to proceed with the next phases of the trial following completion of earlier stages.

CMND-100 is described as a non-hallucinogenic compound based on MEAI being developed as a treatment for alcohol use disorder. The drug candidate is part of what

Clearmind Medicine receives Johns Hopkins approval for CMND-100 trial parts

Tue, 26 May 2026 08:25:29 -0400

CMND-100 is described as a non-hallucinogenic compound based on MEAI being developed as a treatment for alcohol use disorder. The drug candidate is part of what

Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts